The tie up allows GTG to utilize some of its intellectual property and expertise for the development of specific and novel genetic oncology profiling systems to target chemotherapy in late stage cancer patients.
Under the agreement, GTG will to conduct a clinical oncology study and offer these results to its collaboration partner.
GTG CEO Paul MacLeman said this collaboration is a validation of GTG’s capabilities in the area of very low signal to noise nucleic acid analysis.
"The need for companion diagnostics to determine effective treatments for cancer patients is well established," MacLeman said.